Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0292 in non-cystic fibrosis bronchiectasis with chronic Pseudomonas aeruginosa colonization
NL-OMON59465Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD-0292 in bronchiectasis, sponsored by AstraZeneca. Primary endpoint: Annualized rate of moderate-to-severe pulmonary exacerbations. Started Jun 2026; status: recruiting.
02
Drugs
AZD-0292
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NL-OMON59465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59465.